Voyager Therapeutics, Inc. (VYGR) Financials

VYGR Assets vs Liabilities

DateAssetsLiabilities
2023-09-30 294.7 million 118.4 million
2023-06-30 315.5 million 116.5 million
2023-03-31 336.3 million 119.3 million
2022-12-31 159.4 million 100.3 million

VYGR Free Cash Flow and Stock based compensation

Graph available only for supporters. Become a supporter to see it.
DateFree Cash FlowStock based compensation
2023-09-30 -21.8 million 2.9 million
2023-06-30 -2.0 million 2.7 million
2023-03-31 123.1 million 2.6 million
2022-12-31 -13.2 million 2.3 million

VYGR Net Income

No data available :(

VYGR Cash and Debt

Graph available only for supporters. Become a supporter to see it.
DateCashDebtCapital Lease
2023-09-30 252.9 million - 21.0 million
2023-06-30 272.7 million - 21.7 million
2023-03-31 273.3 million - 22.4 million
2022-12-31 118.8 million - 23.1 million

VYGR Shares Outstanding

Graph available only for supporters. Become a supporter to see it.
DateShares Outstanding
2023-09-30 43.9 million
2023-06-30 43.5 million
2023-03-31 42.2 million
2022-12-31 38.5 million

VYGR Expenses

Graph available only for supporters. Become a supporter to see it.
DateCapexR&DG&AS&M
2023-09-30 782000 25.9 million 8.3 million -
2023-06-30 1.2 million 22.0 million 8.3 million -
2023-03-31 509000 18.6 million 9.0 million -
2022-12-31 933000 14.6 million 8.5 million -

VYGR Cost of Revenue

Graph available only for supporters. Become a supporter to see it.
DateRevenueCost of Revenue
2023-09-30 4.6 million 945000
2023-06-30 4.9 million 1.1 million
2023-03-31 150.5 million 1.1 million
2022-12-31 -41.1 million 834000

VYGR

Price: $8.81

52 week price:
6.06
14.34

Earnings Per Share: 2.97 USD

P/E Ratio: 6.42

Exchange: NMS

Sector: Healthcare

Industry: Biotechnology

Volume: 275000

Ebitda: -22.9 million

Market Capitalization: 479.5 million

Links: